Summary:
In patients with type 2 diabetes, flaxseed oil supplementation (FOS) did not lead to statistically significant differences in a cluster of seven measures, including abdominal obesity, hypertension, platelet hyperaggregability, hyperglycemia, and dyslipidemia, based on apolipoprotein E genotypes.
| PICO | Description |
|---|---|
| Population | Patients with type 2 diabetes. |
| Intervention | Flaxseed oil supplementation (FOS). |
| Comparison | Evaluations based on apolipoprotein E genotypes. |
| Outcome | No statistically significant differences were noted in a cluster of seven measures: abdominal obesity, hypertension, platelet hyperaggregability, hyperglycemia, and dyslipidemia among different apolipoprotein E genotypes. |
Source: Douglas E Barre, et al. “Thus far there are no statistically significant differences between various apolipoprotein E genotypes in the cluster of seven responsiveness to a flaxseed oil supplement in persons with type 2 diabetes.” Read article here.
